Breaking News
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
Charity introduces new Hereditary Cancer Risk Tool to fight ovarian cancer

Charity introduces new Hereditary Cancer Risk Tool to fight ovarian cancer

image_pdfDownload PDFimage_print

Ovarian Cancer Action launches its Hereditary Cancer Risk Tool: ovarian.org.uk/risktool

Around 15% of ovarian cancer cases are linked to genetic mutations such as BRCA1, BRCA2 and Lynch Syndrome, which increase an individual’s likelihood of developing ovarian and other cancers. This equates to over 1,000 women a year in the UK whose lives could potentially be saved.

Ovarian Cancer Action has developed its Hereditary Cancer Risk Tool to help people identify their cancer risk. The charity believes everyone has the right to understand if their family history puts them at risk of ovarian and other cancers, as well as the risk-reducing options available.

The tool asks a series of questions regarding an individual’s familial history of cancer and compares answers to the national testing eligibility guidelines. It then, if necessary, clearly explains next steps should an individual choose to pursue testing on the NHS, and reminds every user of the importance of symptoms awareness regardless of their genetic status.

The new tool makes a timely arrival following Theresa May’s ambitious announcement just a few weeks ago, calling on the NHS, Artificial Intelligence sector and health charities to work together to prevent 22,000 deaths each year by 2033. The Prime Minister focused the grand challenge on four cancers commonly diagnosed at a late stage, including ovarian cancer.

Genetic mutations can be passed down through the male or female line to future generations. The general population has a 1 in 400 to 1 in 800 chance of having a BRCA gene mutation. This increases to 1 in 40 in those with Jewish heritage.

When primary school teacher Laura Moses, 28, from London, found out she carried the BRCA1 gene mutation, she was able to trace it back through generations of her family history. Just one year later she was diagnosed with ovarian cancer. She now blogs about her experience at findingcyril.com.

Laura, said:

BRCA has come from my great-grandfather’s side of the family. He had five sisters; two died of breast cancer and three died of ovarian cancer. I’m almost now a voice for those women who came before me in my family who had no idea of the mutation they carried that put them at risk of these cancers” said Laura. “There is not one minute where I question my decision to get tested. It meant I was able to get regular checks. It was very tough to find out about the mutation at age 26, but it allowed me to make choices about my body. We have to remember that knowledge is power.”

Joanne Stanford, Hereditary Cancer Specialist at Ovarian Cancer Action and co-creator of the Hereditary Cancer Risk Tool, said:

Every time a person with a genetic mutation is diagnosed with ovarian cancer, it represents a cancer prevention failure. Along with genetic counselors, we want to ensure individuals can make informed decisions around surveillance, preventative surgeries and its considerations, such as family planning. Genetic testing is one of our strongest weapons in the fight against this disease. To understand your risk of hereditary cancer, visit ovarian.org.uk/risktool. All you need is a few minutes and some information about your family history of cancer; it could change your life.”

Dr Jonathan Krell, Senior Clinical Lecturer in Medical Oncology at Imperial College, said:

Improving the way we select patients for cancer screening and prevention programs, and identifying those people at higher risk of developing cancer is crucial to improving survival rates. This tool will help to increase awareness of genetic abnormalities that people may have been born with that increase their risk of developing cancer, and will encourage more people to consider pursuing genetic testing. The more we know about a person’s risk of developing cancer, the more we can do to try and detect it earlier or prevent it from occurring at all through the use drugs or surgery. Optimizing prevention measures in this group of women is crucial in reducing the rate of deaths from cancer and I believe risk tools such as this will have a significant impact on public health.”

Tagged with:

About author

Related Articles